[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer

Abstract excerpt

Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) breast cancers. Yet, response in these populations remains variable, suggesting clinical utility in developing a better biomarker to select patients for PARPi and predict response. Here, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Imaging and Diagnostics
• Share to Medical Imaging Techniques and Applications
• Share to PARP inhibition in cancer therapy